Birmingham, ALNCT06326476Now EnrollingIRB Ready

Hidradenitis Suppurativa Clinical Trial in Birmingham, AL

Access cutting-edge hidradenitis suppurativa treatment through this early phase 1 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by University of Alabama at Birmingham

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access hidradenitis suppurativa specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hidradenitis suppurativa treatment provided free

Apply for This Birmingham Location

Check if you qualify for this hidradenitis suppurativa clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Hidradenitis Suppurativa Study in Birmingham

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

Male or Female at least 18 years of age, and provide informed consent prior to study procedures.
Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional therapies with a total AN count of greater than or equal to 5 prior to enrollment/randomization
Failed at least 1 course of oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS).
Women of Childbearing potential must have a urine pregnancy test at screening, wk 0 and prior to administration of the study medication
Women of childbearing potential must be willing to continue a highly effective method of birth control throughout the study (oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant).
Negative screening for tuberculosis (TB) (Quantiferon Gold, T-spot) within 3 months prior to screening
If a positive history of latent tuberculosis:
Currently receiving treatment for latent TB per standard of care
Have documentation of having completed treatment within 5 years prior to baseline
Agree not to have a live vaccination during the study.

Exclusion Criteria

Any other active skin disease that in the opinion of the investigator would interfere with the assessment of HS
Have greater than 20 draining fistulas at screening or Day 1 prior to enrollment/randomization
Receipt of non-biologic treatments for HS within 4 weeks prior to baseline other than antibiotics or hormonal therapy
Receipt of biologic agents within 3 months prior to baseline
Receipt of any other investigational product within 3 months prior to baseline
Receipt of new oral antibiotics or hormonal therapy within 6 weeks prior to baseline.
Subjects may be included if they are on steady dose of doxycycline or tetracycline antibiotics only for at least 6 weeks prior to baseline visit and may not change or discontinue dose during course of study.
Receipt of intralesional kenalog injections within 2 weeks prior to baseline
Any uncontrolled diagnosis or condition that in the opinion of the investigator will interfere with the assessments or the study.
Currently has a malignancy or a history of a malignancy within 5 years before screen (except successfully treated non-melanoma skin cancer or cervical carcinoma in situ)
History of an ongoing, chronic or recurrent infectious disease
Are currently pregnant, breastfeeding, or planning to get pregnant during the study.
Previous hypersensitivity reaction to siplizumab or to any of the components
Known infection with HIV, hepatitis B or hepatitis C at screening or randomization. Patients who are Hepatitis B Core antibody and/or Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study.
Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
Any of the following laboratory abnormalities within 30 days of enrollment:
White blood count (WBC) \< 3 x 103/μL;,
CD4+ count below the lower limit of normal,
Platelet count \< 150,000 /μL,
Hemoglobin \< 10 g/dL,
ALT ≥ 2x upper limit of normal (ULN) or
AST ≥ 2x ULN
Serum creatinine \>1.5x ULN in adults.
Positive molecular testing of SARS-CoV-2
ALC less than 800 lymphocytes/mm3

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06326476) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hidradenitis Suppurativa Treatment Options in Birmingham, AL

If you're searching for hidradenitis suppurativa treatment options in Birmingham, AL, this clinical trial (NCT06326476) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced hidradenitis suppurativa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hidradenitis suppurativa clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Birmingham, AL

See all alzheimers disease clinical trials recruiting in Birmingham — not just this study.

Browse Alzheimers Disease Trials in Birmingham →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsHidradenitis Suppurativa TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL